Shopping Cart 0
Cart Subtotal
USD 0

ThromboGenics NV (THR)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

ThromboGenics NV (THR)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company's ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenics's product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. ThromboGenics is headquartered in Leuven, Flemish Brabant, Belgium.

ThromboGenics NV Key Recent Developments

May 02,2017: New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Mar 16,2017: ThromboGenics Business Update-FY 2016

Oct 20,2016: ThromboGenics Business Update-Q3 2016

Sep 07,2016: ThromboGenics Presenting New Ophthalmic Research Data at 16th EURETINA Congress in Copenhagen

Aug 25,2016: ThromboGenics Business Update- H1 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

ThromboGenics NV-Key Facts 6

ThromboGenics NV-Key Employees 7

ThromboGenics NV-Key Employee Biographies 8

ThromboGenics NV-Major Products and Services 9

ThromboGenics NV-Pharmaceutical Pipeline Products Data 10

ThromboGenics NV, Pipeline Products by Therapy Area 10

ThromboGenics NV, Pipeline Products by Development Phase 11

ThromboGenics NV-History 12

ThromboGenics NV-Company Statement 15

ThromboGenics NV-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Section 2-Company Analysis 18

ThromboGenics NV-Business Description 18

ThromboGenics NV-Corporate Strategy 19

ThromboGenics NV-SWOT Analysis 20

SWOT Analysis-Overview 20

ThromboGenics NV-Strengths 20

ThromboGenics NV-Weaknesses 21

ThromboGenics NV-Opportunities 22

ThromboGenics NV-Threats 23

ThromboGenics NV-Key Competitors 24

Section 3-Company Financial Ratios 25

Financial Ratios-Capital Market Ratios 25

Financial Ratios-Annual Ratios 26

Performance Chart 29

Financial Performance 29

Financial Ratios-Interim Ratios 30

Financial Ratios-Ratio Charts 31

Section 4-Company's Lifesciences Financial Deals and Alliances 32

ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32

ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33

ThromboGenics NV, Recent Deals Summary 34

Section 5-Company's Recent Developments 35

May 02, 2017: New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore 35

Mar 16, 2017: ThromboGenics Business Update-FY 2016 36

Oct 20, 2016: ThromboGenics Business Update-Q3 2016 40

Sep 07, 2016: ThromboGenics Presenting New Ophthalmic Research Data at 16th EURETINA Congress in Copenhagen 44

Aug 25, 2016: ThromboGenics Business Update- H1 2016 45

May 13, 2016: ThromboGenics Business Update-Q1 2016 49

May 13, 2016: ThromboGenics Business Update-Q1 2016 52

Section 6-Appendix 55

Methodology 55

Ratio Definitions 55

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

ThromboGenics NV, Pipeline Products by Therapy Area 10

ThromboGenics NV, Pipeline Products by Development Phase 11

ThromboGenics NV, Performance Chart (2012-2016) 29

ThromboGenics NV, Ratio Charts 31

ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32

ThromboGenics NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 33


List Of Table

List of Tables

ThromboGenics NV, Key Facts 6

ThromboGenics NV, Key Employees 7

ThromboGenics NV, Key Employee Biographies 8

ThromboGenics NV, Major Products and Services 9

ThromboGenics NV, Number of Pipeline Products by Therapy Area 10

ThromboGenics NV, Number of Pipeline Products by Development Stage 11

ThromboGenics NV, History 12

ThromboGenics NV, Other Locations 17

ThromboGenics NV, Subsidiaries 17

ThromboGenics NV, Key Competitors 24

ThromboGenics NV, Ratios based on current share price 25

ThromboGenics NV, Annual Ratios 26

ThromboGenics NV, Annual Ratios (Cont...1) 27

ThromboGenics NV, Annual Ratios (Cont...2) 28

ThromboGenics NV, Interim Ratios 30

ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32

ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33

ThromboGenics NV, Recent Deals Summary 34

Currency Codes 55

Capital Market Ratios 55

Equity Ratios 56

Profitability Ratios 56

Cost Ratios 57

Liquidity Ratios 57

Leverage Ratios 58

Efficiency Ratios 58

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

ThromboGenics NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts